MAAT PHARMA SACA (MAAT.PA) Stock Price & Overview
EPA:MAAT • FR0012634822
The current stock price of MAAT.PA is 6.8 EUR. Today MAAT.PA is down by -1.16%. In the past month the price decreased by -4.71%. In the past year, price increased by 13.16%.
MAAT.PA Key Statistics
- Market Cap
- 127.976M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.15
- Dividend Yield
- N/A
MAAT.PA Stock Performance
MAAT.PA Stock Chart
MAAT.PA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MAAT.PA. When comparing the yearly performance of all stocks, MAAT.PA is one of the better performing stocks in the market, outperforming 93.31% of all stocks.
MAAT.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MAAT.PA. MAAT.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
MAAT.PA Earnings
MAAT.PA Forecast & Estimates
11 analysts have analysed MAAT.PA and the average price target is 17.27 EUR. This implies a price increase of 153.93% is expected in the next year compared to the current price of 6.8.
For the next year, analysts expect an EPS growth of -62.16% and a revenue growth 258.42% for MAAT.PA
MAAT.PA Groups
Sector & Classification
MAAT.PA Financial Highlights
Over the last trailing twelve months MAAT.PA reported a non-GAAP Earnings per Share(EPS) of -2.15. The EPS decreased by -4.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.6% | ||
| ROE | -374.74% | ||
| Debt/Equity | 1.43 |
MAAT.PA Ownership
MAAT.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 24.98 | 39.779B | ||
| ARGX | ARGENX SE | 25.05 | 39.754B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.871B | ||
| ABVX | ABIVAX SA | N/A | 7.868B | ||
| 2X1 | ABIVAX SA | N/A | 7.844B | ||
| GLPG | GALAPAGOS NV | N/A | 1.886B | ||
| GXE | GALAPAGOS NV | N/A | 1.883B | ||
| NANO | NANOBIOTIX | N/A | 1.398B | ||
| 6IV | INVENTIVA SA | N/A | 1.174B | ||
| IVA | INVENTIVA SA | N/A | 1.061B | ||
| PHIL | PHILOGEN SPA | 16.85 | 615.502M | ||
| GNFT | GENFIT | N/A | 431.775M | ||
| AYJ | VALNEVA SE | N/A | 408.046M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About MAAT.PA
Company Profile
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 60 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
Company Info
MAAT PHARMA SACA
70 Avenue Tony Garnier
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 63
Phone: 33428291400
MAAT PHARMA SACA / MAAT.PA FAQ
What does MAAT PHARMA SACA do?
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 60 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
What is the stock price of MAAT PHARMA SACA today?
The current stock price of MAAT.PA is 6.8 EUR. The price decreased by -1.16% in the last trading session.
What is the dividend status of MAAT PHARMA SACA?
MAAT.PA does not pay a dividend.
What is the ChartMill rating of MAAT PHARMA SACA stock?
MAAT.PA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of MAAT stock?
MAAT PHARMA SACA (MAAT.PA) operates in the Health Care sector and the Biotechnology industry.
Should I buy MAAT stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MAAT.PA.
What is the employee count for MAAT stock?
MAAT PHARMA SACA (MAAT.PA) currently has 63 employees.